Acute ≥ G3 non-hematologic toxicities | Late ≥ G3 non-hematologic toxicities | Hospitalization | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate Model | Adjusted Model | Univariate Model | Adjusted Model | Univariate Model | Adjusted Model | |||||||
OR (95%CI) | p-value | OR (95%CI) | p-value | OR (95%CI) | p-value | OR (95%CI) | p-value | OR (95%CI) | p-value | OR (95%CI) | p-value | |
Age at diagnosis | ||||||||||||
< 40 | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
40–59 | 0.40 (0.12–1.39) | 0.15 | 0.44 (0.12–1.62) | 0.22 | 0.46 (0.09–2.32) | 0.34 | 0.43 (0.08–2.26) | 0.32 | 0.60 (0.18–1.95) | 0.40 | 0.49 (0.13–1.88) | 0.30 |
60+ | 0.55 (0.15–2.01) | 0.37 | 0.58 (0.15–2.26) | 0.43 | 1.30 (0.25–6.68) | 0.75 | 1.42 (0.27–7.60) | 0.68 | 0.58 (0.17–1.99) | 0.38 | 0.61 (0.15–2.50) | 0.49 |
Race/Ethnicity | ||||||||||||
Caucasian | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
African American | 0.63 (0.35–1.14) | 0.12 | 0.63 (0.34–1.18) | 0.15 | 1.22 (0.48–3.11) | 0.67 | 1.49 (0.57–3.94) | 0.42 | 1.71 (0.94–3.11) | 0.08 | 1.80 (0.90–3.59) | 0.10 |
Hispanic | 1.14 (0.42–3.11) | 0.79 | 1.18 (0.41–3.43) | 0.76 | 1.82 (0.45–7.28) | 0.40 | 1.87 (0.45–7.81) | 0.39 | 1.00 (0.35–2.88) | 0.99 | 0.97 (0.29–3.22) | 0.96 |
Other/ Unknown | 0.69 (0.22–2.11) | 0.51 | 0.77 (0.14–2.48) | 0.66 | 3.64 (0.98–13.56) | 0.05 | 4.62 (1.17–18.22) | 0.03 | 1.11 (0.35–3.55) | 0.86 | 2.66 (0.68–10.31) | 0.16 |
HIV Medication | ||||||||||||
No Protease Inhibitor | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
Protease Inhibitor | 1.38 (0.77–2.46) | 0.28 | 1.34 (0.72–2.48) | 0.36 | 1.27 (0.51–3.16) | 0.61 | 1.55 (0.59–4.07) | 0.37 | 2.44 (1.27–4.65) | < 0.01 | 2.17 (1.04–4.56) | 0.04 |
Year HIV Diagnosed | ||||||||||||
< 2000 | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | ||||||
2000–2009 | 1.05 (0.58–1.91) | 0.87 | 1.44 (0.59–3.49) | 0.42 | 0.81 (0.43–1.51) | 0.51 | ||||||
2010–2016 | 1.28 (0.44–3.72) | 0.65 | 2.12 (0.54–8.36) | 0.28 | 1.38 (0.48–4.03) | 0.55 | ||||||
Smoker | ||||||||||||
Never | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | ||||
Current | 1.06 (0.56–2.00) | 0.87 | 0.68 (0.24–1.89) | 0.46 | 1.41 (0.71–2.80) | 0.33 | 1.74 (0.76–4.01) | 0.19 | ||||
Former | 0.90 (0.40–2.05) | 0.80 | 1.87 (0.61–5.67) | 0.27 | 2.83 (1.20–6.67) | 0.02 | 3.21 (1.19–8.66) | 0.02 | ||||
Unknown | 0.09 (0.01–0.75) | 0.03 | 1.40 (0.25–7.76) | 0.70 | 0.46 (0.09–2.32) | 0.35 | 0.63 (0.11–3.62) | 0.61 | ||||
Stage | ||||||||||||
I | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | ||||
II | 1.37 (0.64–2.95) | 0.41 | 2.77 (0.60–12.76) | 0.19 | 1.32 (0.57–3.03) | 0.52 | 1.14 (0.45–2.89) | 0.78 | ||||
IIIA | 0.70 (0.21–2.29) | 0.55 | 2.13 (0.27–16.48) | 0.47 | 1.66 (0.50–5.47) | 0.41 | 1.20 (0.32–4.52) | 0.79 | ||||
IIIB | 2.14 (0.89–5.15) | 0.09 | 2.43 (0.46–12.81) | 0.30 | 2.60 (1.03–6.54) | 0.04 | 2.14 (0.76–6.00) | 0.15 | ||||
IV | 0.56 (0.10–3.28) | 0.52 | 6.80 (0.77–59.75) | 0.08 | 15.6 (1.66–146) | 0.02 | 16.35 (1.47–181.9) | 0.02 | ||||
Nadir CD4 during Radiation | ||||||||||||
≤ 200 | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | ||||
> 200 | 0.59 (0.31–1.13) | 0.11 | 0.77 (0.29–2.01) | 0.59 | 0.48 (0.24–0.95) | 0.03 | 0.53 (0.24–1.20) | 0.13 | ||||
Unknown | 0.64 (.034–1.22) | 0.18 | 0.49 (0.17–1.43) | 0.19 | 0.40 (0.20–0.80) | < 0.01 | 0.38 (0.17–0.83) | 0.02 | ||||
BMI | ||||||||||||
< 25 | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | ||
25–30 | 0.92 (0.51–1.67) | 0.79 | 1.00 (0.54–1.86) | 0.99 | 0.54 (0.22–1.36) | 0.19 | 1.07 (0.58–1.95) | 0.84 | 0.85 (0.43–1.70) | 0.65 | ||
≥ 30 | 0.37 (0.14–0.95) | 0.04 | 0.43 (0.16–1.14) | 0.09 | – | – | 0.28 (0.09–0.86) | 0.03 | 0.27 (0.07–0.95) | 0.04 | ||
Unknown | 0.95 (0.26–3.46) | 0.94 | 0.88 (0.22–3.53) | 0.85 | 0.55 (0.07–4.60) | 0.58 | 0.62 (0.15–2.54) | 0.51 | 0.75 (0.15–3.68) | 0.72 | ||
Radiation Modality | ||||||||||||
2D + 3D | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | ||||
IMRT | 0.58 (0.31–1.12) | 0.10 | 0.67 (0.34–1.33) | 0.26 | 0.78 (0.29–2.09) | 0.62 | 0.72 (0.37–1.38) | 0.32 | ||||
Unknown | 0.45 (0.23–0.88) | 0.02 | 0.49 (0.24–0.97) | 0.04 | 0.98 (0.37–2.56) | 0.96 | 0.64 (0.32–1.25) | 0.19 | ||||
Chemotherapy Regimen | ||||||||||||
5FU + mitomycin C | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | ||||||
5FU + cisplatin | 0.62 (0.25–1.49) | 0.28 | 1.60 (0.49–5.21) | 0.44 | 1.09 (0.46–2.61) | 0.84 | ||||||
Other | 0.97 (0.46–2.04) | 0.93 | 1.43 (0.49–4.17) | 0.51 | 0.57 (0.25–1.32) | 0.19 |